Hill R J, Oleynek J J, Hoth C F, Kiron M A, Weng W, Wester R T, Tracey W R, Knight D R, Buchholz R A, Kennedy S P
Department of Cardiovascular and Metabolic Diseases, Pfizer Inc., Groton, Connecticut, USA.
J Pharmacol Exp Ther. 1997 Jan;280(1):122-8.
The role of adenosine A1 and A3 receptors in mediating cardioprotection has been studied predominantly in rabbits, yet the pharmacological characteristics of rabbit adenosine A1 and A3 receptor subtypes are unknown. Thus, the rabbit adenosine A3 receptor was cloned and expressed, and its pharmacology was compared with that of cloned adenosine A1 receptors. Stable transfection of rabbit A1 or A3 cDNAs in Chinese hamster ovary-K1 cells resulted in high levels of expression of each of the receptors, as demonstrated by high-affinity binding of the A1/A3 adenosine receptor agonist N6-(4-amino-3-[125I]iodobenzyl)adenosine (125I-ABA). For both receptors, binding of 125I-ABA was inhibited by the GTP analog 5'-guanylimidodiphosphate, and forskolin-stimulated cyclic AMP accumulation was inhibited by the adenosine receptor agonist (R)-phenylisopropyladenosine. The rank orders of potency of adenosine receptor agonists for inhibition of 125I-ABA binding were as follows: rabbit A1, N6-cyclopentyladenosine = (R)-phenylisopropyladenosine > N-ethylcarboxamidoadenosine > or = I-ABA > or = N6-2-(4-aminophenyl) ethyladenosine > > N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide > N6-(4-amino-3-benzyl)adenosine; rabbit A3, N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide > or = I-ABA > > N-ethylcarboxamidoadenosine > N6-2-(4-aminophenyl) ethyladenosine = N6-cyclopentyladenosine = (R)-phenylisopropyladenosine > N6-(4-amino-3-benzyl)adenosine. The adenosine receptor antagonist rank orders were as follow: rabbit A1, 8-cyclopentyl-1,3-dipropylxanthine > 1,3- dipropyl-8-(4-acrylate)phenylxanthine > or = xanthine amine congener > > 8-(p-sulfophenyl)theophylline; rabbit A3, xanthine amine congener > 1,3-dipropyl-8-(4-acrylate)phenylxanthine > or = 8-cyclopentyl-1,3-dipropylxanthine > > 8-(p-sulfophenyl)theophylline. These observations confirm the identity of the expressed proteins as A1 and A3 receptors. The results will facilitate further in-depth studies of the roles of A1 and A3 receptors in adenosine-mediated cardioprotection in rabbits, which can now be based on the appropriate recombinant rabbit A1 and A3 receptor pharmacology.
腺苷A1和A3受体在介导心脏保护中的作用主要是在兔子身上进行研究的,然而兔子腺苷A1和A3受体亚型的药理学特性尚不清楚。因此,克隆并表达了兔子腺苷A3受体,并将其药理学特性与克隆的腺苷A1受体进行了比较。在中国仓鼠卵巢-K1细胞中稳定转染兔子A1或A3 cDNA,导致每个受体的高水平表达,这通过A1/A3腺苷受体激动剂N6-(4-氨基-3-[125I]碘苄基)腺苷(125I-ABA)的高亲和力结合得以证明。对于这两种受体,125I-ABA的结合都被GTP类似物5'-鸟苷亚胺二磷酸抑制,并且腺苷受体激动剂(R)-苯异丙基腺苷抑制了福斯高林刺激的环磷酸腺苷积累。腺苷受体激动剂抑制125I-ABA结合的效价顺序如下:兔子A1,N6-环戊基腺苷 = (R)-苯异丙基腺苷 > N-乙基羧酰胺腺苷 > 或 = I-ABA > 或 = N6-2-(4-氨基苯基)乙基腺苷 > > N6-(3-碘苄基)腺苷-5'-N-甲基脲酰胺 > N6-(4-氨基-3-苄基)腺苷;兔子A3,N6-(3-碘苄基)腺苷-5'-N-甲基脲酰胺 > 或 = I-ABA > > N-乙基羧酰胺腺苷 > N6-2-(4-氨基苯基)乙基腺苷 = N6-环戊基腺苷 = (R)-苯异丙基腺苷 > N6-(4-氨基-3-苄基)腺苷。腺苷受体拮抗剂的效价顺序如下:兔子A1,8-环戊基-1,3-二丙基黄嘌呤 > 1,3-二丙基-8-(4-丙烯酸酯)苯基黄嘌呤 > 或 = 黄嘌呤胺同类物 > > 8-(对磺基苯基)茶碱;兔子A3,黄嘌呤胺同类物 > 1,3-二丙基-8-(4-丙烯酸酯)苯基黄嘌呤 > 或 = 8-环戊基-1,3-二丙基黄嘌呤 > > 8-(对磺基苯基)茶碱。这些观察结果证实了所表达的蛋白质为A1和A3受体。这些结果将有助于进一步深入研究A1和A3受体在兔子腺苷介导的心脏保护中的作用,现在可以基于适当的重组兔子A1和A3受体药理学进行研究。